Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Recent evidence confirms that androgen receptor signalling continues to drive a significant proportion of progressing prostate cancers despite castrate serum levels of testosterone and multiple hormonal interventions. An increased understanding of the molecular biology underlying CRPC is informing on therapeutic targets for this disease, and we hypothesise that this will lead to the development of more efficacious drugs.
to behave as agonists. 14 Continuous oral glucocorticoids (dexamethasone 0.5mg once daily [od] or prednisolone 10mg od) can also result in temporary PSA responses in up to 50% of patients, presumably due to adrenal androgen suppression. [15] [16] [17] A further effective hormone therapy, albeit more toxic, is the use of oestrogens, by mouth or by skin patch. The oestrogenic compound diethylstilboestrol (DES) is not approved for use in the US but is the most commonly used oestrogen in UK practice. Small studies of DES 1mg per day in CRPC reported a response rate of 40-70% of patients. 18, 19 As oestrogens may cause painful gynaecomastia, gastrointestinal upset and, occasionally, fluid retention, and also increase the risk of thromboembolism, they are usually deferred to third-line hormonal therapy.
Treatment with docetaxel 75mg/m 2 three times weekly and daily prednisolone 10mg has been shown to confer a survival advantage of a median of 2.5 months and improve quality of life in patients with CRPC compared with mitoxantrone, and is now regarded as the standard of care in patients for whom chemotherapy is indicated. 16 Platinum-containing regimens such as epirubicin, carboplatin and 5-flurouracil have also shown antitumour activity in phase II studies, 20 and their activity in patients who fail docetaxel treatment is undergoing evaluation. The major impact on the quality of life of most patients with CRPC occurs as a result of their disease metastasising to bone. Single-fraction palliative radiotherapy can be used to control pain from solitary sites of disease. The use of bisphosphonates such as zoledronic acid in prostate cancer remains controversial, and although one study suggests a reduction in skeletal-related complications, overall no improvement in patient quality of life or survival has been reported. 21 For patients with widespread painful bone involvement, treatment with boneseeking radiopharmaceuticals, e.g. strontium-89, is available in specialist centres and offers a targeted approach for providing rapid pain relief. The less myelosuppressive radioisotope, the α-emitter radium 223, is also currently in phase II studies and may be superior to strontium, as administration of higher doses is not as limited by marrow toxicity.
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Optimising the Successful Development of Agents for Castration-resistant Prostate Cancer
The limited therapeutic options available to prostate cancer patients underscore the urgent need for the development of novel agents to tackle the castration-resistant state, provide palliation and improve survival in this group of patients. In addition, drugs that are targeted specifically against cancer cells, allowing a better toxicity profile than standard cytotoxic agents, are sought. The rational development of such novel targeted agents requires a greater understanding of the molecular biology underlying castration resistance. In addition, with the earlier use of castration and the frequent use of PSA for monitoring, the development of CRPC is now commonly identified by an increasing PSA rather than by new or worsening symptoms.
Patients are often asymptomatic when this initially occurs, providing a large cohort of patients who refuse docetaxel or for whom chemotherapy is not suitable and thus presenting a window for the conduct of clinical trials of drugs of low toxicity. 5 The key to drug development lies in identification and characterisation of targets and pathways driving cancer growth in this disease. With our increasing understanding of the genes and pathways that drive CRPC, therapeutic agents can be developed that act on the molecular targets defined by the key genetic and molecular abnormalities responsible. With a plethora of new agents becoming increasingly available, a thorough evaluation of the use of pharmacokinetic (PK) and pharamcodynamic (PD) end-points allows a pharmacological 'audit trail' to be constructed (see Table 1 ). 23 PK end-points provide information on how much drug gets into the body and ideally into target tissues; PD end-points allow understanding of what the drug does with respect to modulation of the molecular target and biochemical pathway, and whether this translates into achieving the desired biological effect. This ensures that all of the main stages in drug development (from drug administration through the biological effect to the clinical outcome)
can be monitored and interpreted. The audit trail thus provides a basis for answering critical questions in a rational, hypothesisdriven fashion and ensures that the drug development process is more scientific and rigorous. As our understanding of the molecular biology of CRPC advances, rational drug development will exploit the targets and pathways of prime importance.
The Androgen Receptor as a Therapeutic Target for Castration-resistant Prostate Cancer
The presence of high AR messenger RNA (mRNA) levels in almost all tumour samples from patients with CRPC strongly suggests that prostate tumours evolve mechanisms to reactivate AR expression and AR-responsive pathways. 14 Molecular changes to the AR that have been proposed to cause castration resistance include R gene amplification, 24 mutations in the AR gene, 6, 25 post-transcriptional causes of increased AR expression 26 and alterations in AR co-repressor/co-activator function. 27, 28 These could result in continued androgen-dependent activation of a 'hyper-sensitive' AR, contribute to the agonist activity that can be observed with these agents. 34 A change in the co-activator to co-repressor ratio can alter AR transactivation activity in the presence of low concentrations of DHT. Conversely, the co-repressors SMRT and NCoR can inhibit AR function in a ligand-dependent manner. Experimental models show that alterations in the co-activator to co-repressor ratio can also explain the paradoxical agonistic effects of anti-androgens and other steroid hormones on prostate cancer growth. 35 However, this relationship has not been exploited therapeutically to date, especially as a result of the complex nature of these interactions. 
Targeting Androgen Receptor Signalling
Inhibition of the Steroid Synthesis Pathway
Plasma testosterone is not completely suppressed by castration, in part due to the peripheral conversion of adrenal androgenic steroids to testosterone by 17-ketoreductase. 4 It has also been reported that, despite castration, intraprostatic levels of androgens in CRPC may remain sufficient to maintain tumour growth. Studies measuring testosterone and DHT report a decline at institution of castration with a subsequent rise in testosterone in CRPC to levels equivalent to prostate tissue obtained from non-castrate men. 41, 42 The source of these androgens is unclear, but altered regulation of A more specific inhibitor of steroid synthesis is currently in phase III clinical development. Abiraterone acetate is a potent, orally bioavailable and irreversible inhibitor of CYP17, which is a key enzyme involved in the 17-hydroxylation of pregnenolone and 
Ablation of Intracellular Androgen Receptor Signalling
HSP90 is a member of the family of heat shock proteins that acts as an adenosine triphosphatase (ATPase)-driven molecular chaperone. can suppress expression of AR-regulated genes. 57 In addition to suppressing AR protein levels in prostate cancer cells, HDAC inhibitors can also block AR activity through inhibition of the assembly of co-activator/RNA polymerase II complex after AR binds to the enhancers of target genes. 57 Several HDACs, including SAHA and romidepsin (depsipeptide), are undergoing clinical investigation.
HSP90 is as an
However, these studies have reported very limited antitumour activity in CRPC. In the recently presented but as yet unpublished phase II trial of romidepsin, a cyclic depsipeptide with pre-clinical prostate cancer antitumour activity administered intravenously weekly for thee weeks in a four-week cycle, only one radiological and biochemical response was observed. 65 However, this may be a reflection of an inadequate pharmacodynamic effect, with current HDAC inhibitors achieving insufficient levels for maximal AR blockade. 57 Improved formulations and further evaluation of the correct schedule could be required to achieve the clinical benefits that have been reported in pre-clinical models.
Targeting Alternative Signalling Pathways
Other Steroid Receptors 
Human Epidermal Growth Factor Receptor 2
Experimental models have shown that the AR can be activated indirectly by cross-talk with other non-steroidal receptors.
Epidermal growth factor receptor, other growth factors such as keratinocyte growth factor, insulin-like growth factor-1 and epidermal growth factor and cytokines such as interleukin-6 can activate the AR and minimise or possibly even negate the requirement for ligand.
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The development of agents to specifically target these upstream genes and proteins potentially deregulated in prostate cancer also provides an opportunity for reversing resistance to endocrine treatments. Human epidermal growth factor receptor 2 (HER-2)/neu, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is consistently over-expressed in some castrate prostate cancer cell lines and in the human disease at a higher frequency in castration-resistant as opposed to hormonenaïve primary tumours. 68, 72, 73 In addition, HER-2/neu was shown to promote DNA binding and AR stability through activation of mitogenactivated protein kinase (MAPK) and Akt, which could also bind directly to the receptor. 74, 75 However, phase II clinical studies of therapeutics targeting HER2 failed to demonstrate any clinical benefit, despite proven antitumour activity with the same dose and regimen in other tumour types. [76] [77] [78] As it becomes increasingly evident that a significant proportion of CRPC remains driven by ligand activation of the AR, the role of cross-talk between the HER kinase family and AR signalling must at best be of limited relevance. However, in the future there may be a role for combination regimens that include therapeutics targeting cross-talk pathways in patients in whom AR signalling has been truly abrogated with CYP17 inhibitors and novel anti-androgens, etc.
Phosphatase and Tensin Homologue and Phosphoinositide 3-kinase Signalling
The phosphoinositide The PI3K pathway appears to be critical in the development of CRPC.
In vitro data suggest that over-expression and activation of AKT can trigger prostate cancer androgen escape via altered sensitivity and activation of AR. 80 The 
Ongoing Challenges
It is envisioned that the next decade will result in significant changes in the treatment of prostate cancer. As new and better drugs targeting the AR are developed (see Table 1 PSA (PSA velocity) has been associated with the length of survival after treatment and may prove to be a suitable surrogate for survival. 87 However, PSA secretion is driven by AR signalling, and new drugs that directly target AR signalling could be ineffective treatments yet modulate PSA levels. New technology allows the isolation and enumeration of circulating tumour cells (CTCs) in patients with advanced prostate cancer. The number of CTCs preand post-chemotherapy above and below a set threshold is associated with survival in CRPC, and a decline in CTC count with treatment is associated with an improvement in survival. 88 Dynamicweighted magnetic resonance imaging and positron emission scans using 18F-fluoro-2-deoxy-D-glucose or 18-F-fluoro-3'deoxy-3'-Lfluorothymidine may also be valuable tools to assess CRPC and may allow early assessment of disease response. Overall, these surrogates could become primary endpoints in efficacy trials, thereby expediting future advances and drug approval. n Improving the Outcome of Patients with Castration-resistant Prostate Cancer
